Kamada Ltd (KMDA) 4.25 $KMDA Kamada Strengthens

New Post Public Reply Private Reply Replies (0) Message Board

Mar 21, 2015 at 9:23 PM

Kamada Ltd (KMDA) 4.25 $KMDA

Kamada Strengthens Leadership Team with the Addition of Vice President-Medical Director
Business Wire - Wed Mar 11, 6:00AM CDT
Kamada Ltd. (NASDAQ:KMDA) (TASE:KMDA), a plasma-derived protein therapeutics company focused on orphan indications, announces that the Company has strengthened its senior leadership team with the appointment of Eran Schenker, M.D. to the newly created position of Vice President-Medical Director Dr. Schenker will report to David Tsur, co-founder and CEO of Kamada.
KMDA: 4.25 (-0.18)

Tracking John Paulson's Paulson & Company Portfolio - Q4 2014 Update
John Vincent - at Seeking Alpha - Mon Feb 23, 3:36AM CST

TLM: 7.61 (-0.04), HHC: 153.71 (+0.46), AET: 108.63 (+0.32), STAY: 19.94 (+0.37), DLTR: 83.81 (+0.41), AEM: 29.72 (+1.16), NPSP: 45.97 (+0.01), DG: 75.78 (+0.87), ABBV: 60.40 (-0.79), TMUS: 33.14 (-0.06), DXM: 5.04 (-0.08), CODE: 38.59 (+0.47), MNK: 132.47 (+1.26), GOLD: 72.18 (+1.60), NCQ: 0.65 (-0.02), COV: 106.71 (-1.36), AU: 9.84 (+0.44), SLXP: 172.80 (+0.26), IAG: 2.03 (+0.04), MYL: 63.06 (-0.88), FDO: 79.90 (+0.20), MGM: 22.62 (-0.23), HIG: 43.10 (+0.53), NG: 3.05 (+0.03), EQIX: 238.95 (+3.05), OAS: 13.80 (-0.16), PETM: 82.98 (+0.03), ACT: 317.06 (+2.65), MDT: 78.02 (+0.36), BPOP: 34.32 (+0.13), ENZY: 7.01 (+0.07), GFI: 4.36 (+0.15), CZR: 9.44 (unch), CVC: 18.68 (+0.59), CIE: 9.07 (-0.03), AGN: 240.22 (+2.88), CACQ: 6.99 (+0.09), T: 33.23 (+0.03), ECA: 11.10 (+0.28), S: 4.95 (-0.04), FCH: 11.91 (+0.51), SHPG: 253.64 (+3.07), DTV: 86.25 (+0.20), KMDA: 4.25 (-0.18), ANV: 0.86 (unch), BAC: 15.84 (+0.23), GRFS: 33.29 (+0.30), HCA: 76.03 (+0.61), POST: 48.54 (+1.40), RDN: 17.03 (+0.22), BEE: 12.95 (+0.34), GLD: 113.57 (+1.28), RLGY: 44.66 (+0.74), HMHC: 23.27 (+0.11), MTG: 9.88 (+0.22), CMCSA: 59.45 (+0.71), SBGL: 9.05 (+0.17), BABA: 85.20 (-0.54)

Quarterly Report Card: New Research on Cisco, PepsiCo, Akamai, Team Health Holdings, and Kamada
PR Newswire - Thu Feb 12, 7:40AM CST
Editor Note: For more information about this release, please scroll to bottom.
AKAM: 72.87 (+0.12), KMDA: 4.25 (-0.18), TMH: 59.25 (+0.66), CSCO: 28.44 (+0.18), PEP: 95.34 (+1.24)

Kamada ups EPS 25% in Q4
Seeking Alpha - at Seeking Alpha - Wed Feb 11, 9:12AM CST

KMDA: 4.25 (-0.18)

Kamada misses by $0.03, beats on revenue
Seeking Alpha - at Seeking Alpha - Wed Feb 11, 6:38AM CST

KMDA: 4.25 (-0.18)

Kamada Reports 2014 Fourth Quarter and Full Year Financial Results
Business Wire - Wed Feb 11, 6:01AM CST
--Conference call begins today at 8:30 a.m. Eastern time
KMDA: 4.25 (-0.18)

Kamada reports February 11, reaffirms revenue guidance
Seeking Alpha - at Seeking Alpha - Thu Feb 05, 10:19AM CST

KMDA: 4.25 (-0.18)

Kamada Affirms 2014 Revenue Guidance
Business Wire - Thu Feb 05, 9:11AM CST
Kamada Ltd. (NASDAQ:KMDA) (TASE:KMDA), a plasma-derived protein therapeutics company focused on orphan indications, today affirms 2014 revenue guidance and announces that the Company will release financial results for the three and twelve months ended December 31, 2014 prior to the market open on Wednesday, February 11, 2015.
KMDA: 4.25 (-0.18)

Kamada Reports Encouraging Interim Data from its Phase 1/2 Extension Study: AAT in Pediatric Patients with Type 1 Diabetes
Business Wire - Mon Feb 02, 7:01AM CST
Kamada Ltd. (NASDAQ:KMDA) (TASE:KMDA), a plasma-derived protein therapeutics company focused on orphan indications, today reported additional data from the Company's ongoing extension study of its open-label Phase 1/2 clinical trial with its lead product, intravenous Alpha1-Proteinase Inhibitor-Human (AAT), to treat recently diagnosed type 1 diabetes (T1D) pediatric patients . Treatment of T1D patients with Kamada's AAT may have several medical benefits including slowing the progression of the disease, improved metabolic control, reduction of daily insulin dose requirements, and most importantly, reduction of diabetes complications.
KMDA: 4.25 (-0.18)

Can John Paulson Bounce Back in 2015? Investments in Health Care and Pharmaceuticals Could Help
at The Street - Mon Jan 12, 8:31AM CST
Billionaire investor John Paulson's portfolio took a beating in 2014. A look at his equities holdings reveals why.
KOG: 6.56 (-0.39), ANV: 0.86 (unch), WLL: 39.03 (-1.04), VRX: 204.26 (+2.17), NCQ: 0.65 (-0.02), VNDA: 9.57 (-0.21), FDO: 79.90 (+0.20), VOD: 33.96 (+0.81), CIE: 9.07 (-0.03), AGN: 240.22 (+2.88), S: 4.95 (-0.04), SHPG: 253.64 (+3.07), AOL: 40.52 (-0.63), KMDA: 4.25 (-0.18), ABBV: 60.40 (-0.79), DG: 75.78 (+0.87), TWC: 157.87 (+2.26), TMUS: 33.14 (-0.06), VZ: 49.56 (+0.26), CMCSA: 59.45 (+0.71), OAS: 13.80 (-0.16)

Kamada Reports Encouraging Discussions with European Co-Rapporteurs Regarding European Filing for Inhaled Alpha-1 Antitrypsin to Treat AATD
Business Wire - Wed Jan 07, 6:00AM CST
Kamada Ltd. (NASDAQ:KMDA) (TASE: KMDA), a plasma-derived protein therapeutics company focused on orphan indications, today provides a clinical/regulatory update.
KMDA: 4.25 (-0.18)

Kamada set for gap up at the open
Seeking Alpha - at Seeking Alpha - Mon Jan 05, 7:43AM CST

KMDA: 4.25 (-0.18)

Kamada Announces Positive Interim Results from Phase I/II Clinical Study of its Human Alpha-1 Antitrypsin to Treat Graft-versus-Host Disease Presented at the American Society of Hematology Annual Meeting
Business Wire - Thu Dec 11, 6:01AM CST
Kamada Ltd. (NASDAQ:KMDA) (TASE:KMDA), a plasma-derived protein therapeutics company focused on orphan indications, reports that interim data from a Phase I/II clinical study of the Company's proprietary human Alpha-1 Antitrypsin (AAT) conducted by the Fred Hutchinson Cancer Research Center in Seattle, Washington, for the treatment of graft-versus-host-disease (GvHD) were highlighted in a poster presentation at the 56th American Society of Hematology Annual Meeting and Exposition that was held from December 6-9, 2014 in San Francisco.
KMDA: 4.25 (-0.18)

Rabies Therapeutic Market Pipeline Overview, Assessment, Key Players & Drugs Profiles H2 2014
PRWeb - Wed Nov 12, 8:30PM CST
The report "Rabies - Pipeline Review, H2 2014" provides comprehensive information on the therapeutic development for Rabies, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Rabies and special features on late-stage and discontinued projects. Complete Report is Available @ http://www.rnrmarketresearch.com/rabies-pipel...eport.html .
NVAX: 9.58 (-0.13), KMDA: 4.25 (-0.18), VBIV: 2.85 (-0.06), NNVC: 2.58 (-0.14), SVA: 5.02 (+0.03)

Kamada set for gap down at the open
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 7:47AM CST

KMDA: 4.25 (-0.18)

Kamada Adj. Net loss of $1.9M, misses on revenue
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 6:40AM CST

KMDA: 4.25 (-0.18)

Kamada Announces Third Quarter 2014 Financial Results
Business Wire - Wed Nov 12, 6:01AM CST
--Conference Call Begins Today at 8:30 a.m. Eastern Time
KMDA: 4.25 (-0.18)

Kamada reports November 12
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 7:44AM CST

KMDA: 4.25 (-0.18)

Kamada to Host Third Quarter 2014 Financial Results Conference Call on November 12, 2014
Business Wire - Mon Nov 10, 6:01AM CST
Kamada Ltd. (NASDAQ:KMDA)(TASE:KMDA), a plasma-derived protein therapeutics company focused on orphan indications, announces that it will release financial results for the three and nine months ended September 30, 2014 prior to the market open on Wednesday, November 12, 2014.
KMDA: 4.25 (-0.18)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Govee's Retro Holiday Lights: A Festive Nostalgia Trip

Ah, the holidays—they're creeping up like a kid sneaking downstairs for a peek at their gifts. But it's not the gifts under the tree that brighten a room, it's those lights draping the tree itself. Enter Govee, bringing us back to that vintage glow we all remember from our childhoods. They've teamed up with Brady Tolbert, a design whiz who can make a living room look...

Artprice Champions Creative Freedom with AI in 2026

AI and the Creative Reawakening As the autumn of 2026 rolls in, publishing circles are buzzing over artificial intelligence's role in artistry. Weekly updates hailing rejection, tolerance, or adaptation of AI in writing stir the pot. Yet, Artprice by Artmarket stands out by anchoring creative freedom and responsibility in the spotlight. Grounded on an initiative launched...

Ericsson Executes Bold Share Buyback Plan in Oct.

Ericsson Kicks Off October with Major Share Repurchases Ericsson's taking bold steps in consolidating shareholder value, and folks, this ain't your run-of-the-mill stock-in-the-drawer move. Between October 19 and 23, 2026, Ericsson picked up 500,000 of its own Class B shares. Yep, you heard right—half a million shares just like that, with a neat price tag rounding out...

Coastal Financial Faces Lawsuit Amid Massive Stock Hit

Coastal Financial Corporation's (NASDAQ:CCB) recent nosedive is more distressing than a rollercoaster ride. After a 43.52% stock drop, investors are furious, to say the least. What tipped the scales? Coastal's financial revelations painted a bleak picture, but that’s just scratching the surface of a mess that has folks heading for legal battles. Behind the Numbers: The...

SUNON's Approach to AI-Driven Workspaces Debuted at ORGATEC

SUNON's Unique Spin on Future Workspaces The world of workplace solutions is buzzing with ideas on how to blend smart tech with soulful spaces. This year, SUNON is hitting ORGATEC 2026 in Cologne with a bold approach that stitches AI, nature, and circular design right into the fabric of office life. They’re not just setting up shop; they’re promising a peek into a...

Coastal Faces Legal Storm: Investors Eyeing the Clock

Coastal Financial in the Crosshairs The stakes are big, folks. Coastal Financial Corporation (NASDAQ: CCB) is caught in a storm, and it's not a gentle breeze. A securities class action has hit the table, and it's drawing in investors like seagulls to a beach picnic. What Lit the Match? The story kicks off with a plummet so dramatic it turned heads and wallets upside...

Decoding the Risks and Rewards of Older Homes

Cracking Open the Older Homes Enigma You've got these older homes—charm oozing out of every nook and cranny but potential pitfalls hidden beneath every surface. I'm talking about that irresistible lure of historic details that come with a side of risk. Now, before you jump in with both feet, you might want to pause and consider what Lee Malcom from Malcom & Malcom...

ASICS and University of Michigan Launch Innovation Lab

Running Innovation Gets a Boost in Ann Arbor On a crisp fall day up in Ann Arbor, ASICS and the University of Michigan have decided it's high time to shake up the world of running product R&D. These two powerhouses just launched the ASICSx Michigan Sport Innovation Center (AMSI), an academic-industry research lab. It's like they're mixing college smarts with business...

Bank of America Faces Class-Action Suit in Court

Mixed Bag for Bank of America Investors If you thought you could just park your cash in big banks and slumber through the financial year, think again. Bank of America (NYSE: BAC) has found itself in hot water with a securities fraud class-action suit looming over what some are calling a pretty nasty oversight in compliance. A 4.76% stock drop was a bitter sip for those...

Dar Global Eyes Dubai for Strategic Real Estate Moves

Tapping into Dubai's Real Estate Allure Every seasoned investor knows the real estate game ain't for the faint of heart, especially when you’re playing in a market as competitive as Dubai's. But here comes Dar Global Capital Partners (DGCP), throwing their hat into the ring with a fresh strategy centered around high-value real estate. Sure, they aren't new to the...